Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.41 |
| ▸ | BRD2 | P25440 | 5/20 | 0.40 |
| ▸ | BRD3 | Q15059 | 5/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.34 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.33 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | RHEB | Q15382 | 1/20 | 0.32 |
| ▸ | CBFB | Q13951 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16019682 | 0.76 | RECQL (0.44) | BRD4BRD2BRD3UTS2RPDE3B | |
| SCHEMBL16009074 | 0.76 | BRD4 (0.63) | BRD4BRD2BRD3DYRK1AALDH1A1 | |
| SCHEMBL16156577 | 0.74 | ERBB2 (0.49) | BRD4BRD2BRD3 | |
| SCHEMBL17204317 | 0.74 | BRD4 (0.43) | BRD4BRD2BRD3PDE3BPDE3A | |
| SCHEMBL16156559 | 0.70 | UTS2R (0.54) | UTS2RALDH1A1 | |
| SCHEMBL18947827 | 0.67 | BRD4 (0.40) | BRD4BRD2BRD3HIPK2DYRK1A | |
| SCHEMBL16010482 | 0.65 | DYRK1A (0.51) | BRD4BRD2BRD3DYRK1AMAOA | |
| SCHEMBL16009339 | 0.65 | KDM4E (0.57) | BRD4BRD2BRD3DYRK1AALDH1A1 | |
| SCHEMBL20580770 | 0.64 | CTSV (0.58) | BRD4BRD2BRD3PDE3BPDE3A | |
| SCHEMBL16795087 | 0.64 | NUDT1 (0.46) | PDE3BPDE3ARHEB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-05 | — | — | US | disclosed |
| US-9675697-B2 | BET bromodomain inhibitors and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-06-13 | — | — | US | disclosed |
| US-20140256706-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281773-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | BRD4, BRDT, BRD3 | BRD4 1/4885BRD2 6/4885BRD3 3/4885 |
| US-20140256706-A1 | BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME | BRD4, BRDT, BRD3 | BRD4 1/4885BRD2 6/4885BRD3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.